Notably, it has been reported that sensitivity of uveal melanoma to EZH2 inhibitors is independent of BAP1 mutational status (31), suggesting a lineage-specific effect of BAP1 on the activity of EZH2i (EZH2 inhibitors). This evidence concerns the gene EZH2 and uveal melanoma.